A Service For Professionals Thursday, July 27, 2017
Call (202) 540-8337
A Service For Professionals Thursday, July 27, 2017 11306 Sources 394,765,137 Articles 3,384,471 Readers
Call (202) 540-8337

Cancer Vaccines Summit to be chaired by Dr Joseph Melenhorst from the University of Pennsylvania

Cancer Vaccines 2014

Cancer Vaccines 2014

Cancer Vaccines 2014; Quantify Strategies to Enhance Cancer Vaccine Research and Development, 15th - 16 September, London UK

All sessions are incredibly exciting”
— Dr Jos Melenhorst, University of Pennsylvania

LONDON, LONDON, UNITED KINGDOM, August 6, 2014 /EINPresswire.com/ -- In the run up to SMi’s 3rd annual event on Cancer Vaccines, industry KOL Dr Jos Melenhorst from the University of Pennsylvania, was asked a few questions about the conference taking place on 15th and 16th September and about the Cancer Vaccines industry.

Jos Melenhorst will be chairing the conference and will also be providing key insights into the "perfect partnership" with Novartis. The university director from the Product Development & Correlative Sciences Laboratory will speak on combination therapy, T cells and infusion of cells following chemotherapy.

The Product Development & Correlative Sciences Laboratory improves cellular immune therapy efficacy tracking the expansion, persistence, homing, and the quality of chimeric antigen receptor-expressing T (CART) cells, response of the tumor to therapy, and biomarkers of response. In addition Joseph Melenhorsts team assess the quality attributes of the starting material and end product of cell manufacturing again for markers that predict clinical efficacy. This information feeds back into cell manufacturing.

When asked about the strengths of Cancer Vaccines 2014, Dr Melenhorst highlighted cutting edge tumor vaccine development plus insights into analytical methodologies that drive the improvement of cancer vaccines as key updates.

“The most interesting sessions in this conference? Tough call to make since all sessions are incredibly exciting, but if I would have to make a choice it would be improving the success in vaccine research & development.”

When asked what he thought the biggest challenges are in the industry today, he said:
“Moving the proof-of-concept vaccines into a pre-emptive vaccination strategy. Vaccinating a patient who has a high tumor burden may be not the best timing of this approach. The future for cancer vaccines? Pre-emptive vaccination, adjuvants for response amplification/potentiation and combination therapies.”

The full interview is available to read in the event download tab at www.cancer-vaccinesevent.com

Confirmed attendees include: Amal Therapeutics, Amgen, Boehringer Ingelheim RCV GmbH & Co KG, Breast International Group, Cancer Research UK, Cancer Vaccines Ltd, Crucell Vaccine Institute, Curevac GmbH, DanDrit Biotech, EGIS Pharmaceuticals, GSK, Hybrid Systems, Immatics Biotechnologies, Immudex, Immunicum, KACST, MediGene, Scancell, St George Hospital, Theravectys, University Of Pennsylvania, University Of Southampton, University Of Tuebingen, Vaccinogen, Valneva, XEME Biopharma plus many more..

For further details on Cancer Vaccines 2014, visit www.cancer-vaccinesevent.com

Cancer Vaccines
15TH & 16TH SEPT 2014
Holiday Inn Regents Park, London UK
www.cancer-vaccinesevent.com

--end--

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world?s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.
More information can be found at http://www.smi-online.co.uk

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here

Powered by EIN Presswire